Medtronic’s cardiac resynchronisation therapy-pacemaker, Viva CRT-P. Credit: Medtronic.

Medtronic has reported positive results from a real-world study of the effects of its AdaptivCRT algorithm on patients suffering from heart failure.

In the study with 1,835 participants, the use of the AdaptivCRT algorithm demonstrated a 31% relative decrease in all-cause mortality compared to standard cardiac resynchronisation therapy (CRT).

Related Company Profiles

View all

AdaptivCRT is designed to personalise therapy by adjusting the implanted CRT device’s pacing capability based on a minute-to-minute assessment of an individual patient’s rhythm.

“It minimised a patient’s odds of a 30-day heart failure re-admission by 59%, increased CRT response rate, decreased unnecessary right ventricular pacing and enhanced outcomes for patients with normal AV conduction.”

It is being further studied in a randomised clinical trial called AdaptResponse for superiority over traditional CRT.

In previous analyses, the algorithm is said to have shown a 46% reduction in atrial fibrillation (AF) episodes, lasting more than 48 hours when compared to patients treated with conventional CRT.

It was also found to minimise a patient’s odds of a 30-day heart failure re-admission by 59%, increase CRT response rate, decrease unnecessary right ventricular pacing and enhance outcomes for patients with normal AV conduction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “With AdaptivCRT, we are treating heart failure comprehensively, with technology designed to address the individual needs of each patient.

“This analysis shows yet another benefit of AdaptivCRT, and we look forward to results from the randomised, superiority AdaptResponse trial in the coming years.”

The company’s heart failure portfolio comprises CRT devices such as MR-conditional CRT-Ds and CRT-Ps, mechanical circulatory support therapy, diagnostics and expert analysis via Care Management Services.